Intracellular peptides in cell biology and pharmacology

Publication type
Access rights
Open Access
Appears in Collections:
Intracellular peptides are produced by proteasomes following degradation of nuclear, cytosolic, and mitochondrial proteins, and can be further processed by additional peptidases generating a larger pool of peptides within cells. Thousands of intracellular peptides have been sequenced in plants, yeast, zebrafish, rodents, and in human cells and tissues. Relative levels of intracellular peptides undergo changes in human diseases and also when cells are stimulated, corroborating their biological function. However, only a few intracellular peptides have been pharmacologically characterized and their biological significance and mechanism of action remains elusive. Here, some historical and general aspects on intracellular peptides’ biology and pharmacology are presented. Hemopressin and Pep19 are examples of intracellular peptides pharmacologically characterized as inverse agonists to cannabinoid type 1 G-protein coupled receptors (CB1R), and hemopressin fragment NFKF is shown herein to attenuate the symptoms of pilocarpine-induced epileptic seizures. Intracellular peptides EL28 (derived from proteasome 26S protease regulatory subunit 4; Rpt2), PepH (derived from Histone H2B type 1-H), and Pep5 (derived from G1/S-specific cyclin D2) are examples of peptides that function intracellularly. Intracellular peptides are suggested as biological functional molecules, and are also promising prototypes for new drug development.
de Araujo CB, Heimann AS., Remer RA., Russo LC., Colquhoun A, Forti FL., et al. Intracellular peptides in cell biology and pharmacology. Biomolecules. 2019 Apr;9(4),150. doi:10.3390/biom9040150.
Link to cite this reference
Journal title
Issue Date

Files in This Item:

Size: 1.64 MB
Format: Adobe PDF
Show full item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.